Physician profile
Mark G Treuth
NPI 1598757619
$7,970.97
in general payments reported to CMS, 2019-2025
33 companies · $1,057 in 2025
The $1,057 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,569 · 2020: $516 · 2021: $653 · 2022: $949 · 2023: $1,317 · 2024: $910 · 2025: $1,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,265 · Education: $18.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,264.73 |
| Education | $18.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $2,186.97 | 2019 | |
| Novartis Pharmaceuticals Corporation | $664.34 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $573.99 | 2019-2025 | Jardiance |
| Amgen INC. | $468.83 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $467.73 | 2019-2025 | Lifevest |
| Abiomed | $389.64 | 2022-2025 | Impella |
| Medtronic, INC. | $354.96 | 2021-2024 | Corevalve Evolut R, Linq II, Telescope |
| Janssen Pharmaceuticals, INC | $338.78 | 2019-2023 | Xarelto |
| Boston Scientific Corporation | $315.75 | 2021-2025 | Watchman Access System, Watchman Flx |
| Pfizer INC. | $285.31 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $246.74 | 2019-2025 | Camzyos, Eliquis |
| Scpharmaceuticals INC. | $233.14 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $219.51 | 2021-2025 | Farxiga, Brilinta |
| Abbott Laboratories | $159.77 | 2020-2025 | Xience Skypoint, Thoratec Heartmate 3 Lvas Implant Kit, Diamondback Coronary |
| Chiesi USA, INC. | $142.79 | 2020-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $132.99 | 2022 | |
| Irhythm Technologies, INC. | $119.41 | 2019-2024 | Zio Xt Patch, Zio Monitor |
| Merck Sharp & Dohme LLC | $110.33 | 2021-2024 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $89.26 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $87.86 | 2024 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $55.51 | 2023-2024 | Inpefa |
| Esperion Therapeutics, INC. | $48.47 | 2021-2022 | |
| Amarin Pharma, INC. | $47.66 | 2019-2020 | |
| Lundbeck LLC | $44.67 | 2019 | |
| Bridgebio Pharma, INC. | $33.17 | 2025 | Attruby |
| Gilead Sciences, INC. | $27.25 | 2019 | |
| Alnylam Pharmaceuticals INC. | $24.63 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $18.99 | 2023 | Evkeeza |
| Kowa Pharmaceuticals America, INC. | $18.07 | 2021 | |
| Philips North America LLC | $17.54 | 2022 | |
| Biotronik INC. | $17.17 | 2019 | |
| Novo Nordisk INC | $15.69 | 2025 | Wegovy |
| Watermark Medical, INC. | $14.05 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Treuth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.